Williams Jones Wealth Management LLC. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 185,782 shares of the biopharmaceutical company's stock after selling 14,646 shares during the period. Williams Jones Wealth Management LLC.'s holdings in Pfizer were worth $4,929,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the business. Rialto Wealth Management LLC purchased a new position in Pfizer during the 4th quarter valued at $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at about $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the fourth quarter valued at about $28,000. Noble Wealth Management PBC bought a new position in Pfizer in the fourth quarter worth about $31,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer in the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Analysts Set New Price Targets
A number of research firms have weighed in on PFE. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $29.17.
View Our Latest Report on PFE
Pfizer Price Performance
Shares of PFE opened at $23.51 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a market capitalization of $133.66 billion, a P/E ratio of 16.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The firm has a 50 day moving average of $23.56 and a 200 day moving average of $25.27. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. During the same quarter in the previous year, the business earned $0.82 earnings per share. The company's revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.32%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
